LETTER TO THE EDITOR

Coinfection with SARS-CoV-2 and other respiratory pathogens in patients with COVID-19 in Guangzhou, China

To the Editor,

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a global pandemic and remains as a major public health issue.1 As of 20 May 2020, data from the World Health Organization (WHO) have shown that more than 4735,622 confirmed cases have been identified in 216 countries/regions.2 Previous studies have found that the immune system is damaged when the human body is infected with influenza virus, which may lead to

### TABLE 1  Baseline characteristics of study population

| Characteristic                   | Total (n = 32) | Coinfection (n = 14) | Noncoinfection (n = 18) | P* |
|---------------------------------|---------------|----------------------|-------------------------|----|
| Age, y                          |               |                      |                         |    |
| 52 (41.65)                      | 57 (47.69)    | 48 (38.59)           |                         | .367|
| Male sex no.(%)                 |               |                      |                         |    |
| 20 (62.5%)                      | 11 (78.6%)    | 9 (50.0%)            |                         | .098|
| ICU admission                   |               |                      |                         |    |
| 13 (40%)                        | 11 (78.6%)    | 2 (11.1%)            |                         | <.001|
| Symptom                         |               |                      |                         |    |
| Fever                           | 22 (68.8%)    | 10 (71.4%)           | 12 (66.7%)              | 1.000|
| cough                           | 23 (71.9%)    | 9 (64.3%)            | 14 (77.8%)              | .453|
| Expectoration                   | 19 (59.4%)    | 8 (57.1%)            | 11 (61.1%)              | 1.000|
| Thoracalgia                     | 1 (3.1%)      | 0                    | 1 (5.6%)                |    |
| Rhinobyon/pharyngalgia          | 4 (12.5%)     | 1 (7.1%)             | 3 (16.7%)               |    |
| Headache                        | 1 (3.1%)      | 0                    | 1 (5.6%)                |    |
| Dyspnea                         | 12 (37.5%)    | 8 (57.1%)            | 4 (22.2%)               | .068|
| Breathlessness                  | 9 (28.1%)     | 7 (50.0%)            | 2 (11.1%)               | .022|
| Myalgia                         | 7 (21.9%)     | 3 (21.4%)            | 4 (22.2%)               | 1.000|
| Fatigue                         | 7 (21.9%)     | 3 (31.4%)            | 4 (22.2%)               | 1.000|
| Diarrhea                        | 3 (9.4%)      | 2 (14.3%)            | 1 (5.6%)                |    |
| Conscious disturbance           | 3 (9.4%)      | 2 (14.3%)            | 1 (5.6%)                |    |
| Complication                    |               |                      |                         |    |
| ARDS                            | 10 (31.3%)    | 9 (64.3%)            | 1 (5.6%)                | .001|
| Shock                           | 5 (15.6%)     | 5 (35.7%)            | 0                       | .012|
| Acute renal injury              | 6 (18.8%)     | 5 (35.7%)            | 1 (5.6%)                | .064|
| Radiographic findings           |               |                      |                         |    |
| GGO only                        | 11 (34.4%)    | 3 (21.4%)            | 8 (44.4%)               | .025|
| GGO + consolidation             | 17 (53%)      | 11 (78.6%)           | 6 (33.3%)               |    |
| Consolidation                   | 4 (12.5%)     | 0                    | 4 (22.2%)               |    |
| Respiratory support             |               |                      |                         |    |
| No need                         | 7 (21.9%)     | 1 (7.1%)             | 6 (33.3%)               | .003|
| Nasal catheter oxygen           | 12 (37.5%)    | 2 (14.3%)            | 10 (55.6%)              |    |
| Noninvasive ventilation         | 3 (9.4%)      | 3 (21.4%)            | 0                       |    |
| Invasive ventilation            | 6 (18.8%)     | 4 (28.6%)            | 2 (11.1%)               |    |
| ECMO                            | 4 (12.5%)     | 4 (28.6%)            | 0                       |    |

Abbreviations: ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; GGO, ground-glass opacity; ICU, intensive care unit.

*Comparison of clinical characteristics between patients with COVID-19 with and without coinfection.
coinfection of bacteria and even secondary fungal coinfection, with high mortality. Cases of coinfection with SARS-CoV-2 and other respiratory pathogens have also been recently reported in China. We herein report 14 cases of COVID-19 coinfected with other respiratory pathogens and compare the clinical characteristics and laboratory results of patients with COVID-19 with or without coinfection in Guangzhou, China.

In this study, we included 32 confirmed COVID-19 cases between 1 January and 1 March 2020. Demographic, clinical, and radiological features and laboratory data were collected. Pathogenic species in sputum specimens that were collected from 10 to 25 days of onset of symptoms and single sample from each patient, were identified by the reverse transcription polymerase chain reaction and culture. Among these cases, 14 patients were infected with other pathogens, including viral, bacterial, and fungal infections. Five cases were infected with the respiratory syncytial virus (RSV), human parainfluenza virus (HPIV), human metapneumovirus (hMPV), rhinovirus (rRVh), and enterovirus (EV) (Table S1), which are prevalent in children and infants; however, these viruses are also common in adults with immunodeficiency. Whether infections by these viruses were also due to the immunodeficient state of patients with COVID-19 was unclear. Moreover, we found two interesting cases of coinfection with CoV-HKU1 (Table S1), which is a β-coronavirus A strain and has a genome structure that is similar to that of other coronaviruses of the β group, and has been previously reported. This indicates that this subject was simultaneously infected with two different β-group coronaviruses. Ten patients with COVID-19 (31%) were infected with opportunistic pathogenic bacteria, including gram-negative bacteria Staphylococcus epidermidis, and Acinetobacter baumannii. Candida albicans infection was also common among these patients (Table S1). This finding suggests that we need to pay additional attention to the possibility of secondary infections in severe patients and take appropriate measures to prevent the occurrence of this situation.

Our results showed that the proportion of intensive care unit (ICU) patients in patients with COVID-19 with other respiratory pathogen infections was significantly higher than those without other respiratory pathogen infections (P < .05) (Table 1). The differences of symptoms between the two groups were manifested mainly in the breathing of patients, and patients with COVID-19 with coinfections presented with more severe difficulty in breathing (P < .05) (Table 1). In addition, patients with COVID-19 with coinfection were more likely to have complications such as acute respiratory distress syndrome and shock (P < .05) (Table 1). The computed tomography images of patients with COVID-19 with coinfection were more complicated and diverse and were different from those of patients without coinfection.

Further comparison of laboratory results between patients with COVID-19 with and without coinfection showed that lymphocyte and platelet counts of coinfected patients with the novel coronavirus were significantly lower than those of patients without coinfection (P < .05) (Table S2), and lymphocytopenia was identified as a risk factor for coinfection during COVID-19 (Table S3). Since the outbreak of COVID-19, a significant reduction in lymphocyte counts in peripheral blood has been clinically observed in many cases of COVID-19, which has been listed as one of the laboratory indicators by clinical guidelines. A study of 1099 patients with COVID-19 showed that lymphocytopenia was present in 83.2% of the patients on admission. Lymphocytes play an important role in the body’s adaptive immunity against a variety of pathogens. The emergence of lymphocytopenia in patients with COVID-19 results in a state of immunodeficiency, which makes it easier to be coinfected with other respiratory pathogens, including viruses, bacteria, and even fungi. A recent preprint study showed that human primary peripheral blood monocytes are not susceptible to SARS-CoV-2 because viral replication was not detected in human immune cells. Interestingly, SARS-CoV-2 virus-like particles were observed in primary CD4+ T cells by electron microscopy. Sepsis leads to large amounts of proinflammatory and anti-inflammatory cytokines, which induce reduced lymphocyte apoptosis and chronic immune responses. The cause of the lymphocytic reduction in patients with COVID-19 may be related to the excessive immune response and cytokine storm.

In summary, we must be alert to the occurrence of coinfection in patients with COVID-19, especially in severe ICU patients. Lymphocytopenia may play an important role in the occurrence of coinfection, which deserves additional research to explore its potential mechanisms and the impact on the pathogenesis of patients with COVID-19.

ACKNOWLEDGMENT
This study was supported by the Scientific and Technological Emergency Special of Guangdong Province for Prevention and Controlling of COVID-19 (Grant number: 2020B1111340004).

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.

Zhengtu Li
Zhao-ming Chen
Ling-Dan Chen
Yang-Qing Zhan
Shao-Qiang Li
Jing Cheng
Ai-ru Zhu
Li-Yan Chen
Nan-Shan Zhong
Shi-Yue Li
Wen-Ju Lu
Feng Ye

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Correspondence
Feng Ye, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Xi Road, 510120 Guangzhou, China.
Email: yefeng@gird.cn

ORCID
Zhengtu Li  https://orcid.org/0000-0001-5584-7223
Feng Ye  https://orcid.org/0000-0002-5953-6024

REFERENCES
1. Lai C, Shih T, Ko W, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Ag. 2020;55:105924.
2. Coronavirus disease (COVID-19) outbreak situation. Data as received by WHO from national authorities by 10:00 CEST. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
3. Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med. 2012;40(5):1487-1498. https://doi.org/10.1097/CCM.0b013e3182416f23
4. Chaung J, Chan D, et al. Coinfection with COVID-19 and coronavirus HKU1—the critical need for repeat testing if clinically indicated. J Med Virol. 2020:1-2. https://doi.org/10.1002/jmv.25890
5. Blasco ML, Buesa J, et al. Co-detection of respiratory pathogens in patients hospitalized with coronavirus viral disease-2019 pneumonia. J Med Virol. 2020;1-3. https://doi.org/10.1002/jmv.25922
6. Nowak MD, Sordillo EM, et al. Co-infection in SARS-CoV-2 infected patients: where are influenza virus and rhinovirus/enterovirus? J Med Virol. 2020:1-2. https://doi.org/10.1002/jmv.25953
7. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020:1-7. https://doi.org/10.1002/jmv.25781
8. Koehler P, Cornely OA, Bottiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63(6):528-534. https://doi.org/10.1111/myc.13096
9. Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol. 2005;79:884-895.
10. Prevention CCfDCa. The Guideline of Diagnosis and Treatment of COVID-19. 2020. http://www.chinacdc.cn/jkzt/crb/xcrxjb/202002/t20200209_212396.html. Accessed February 9, 2020.
11. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol 2020:1-2. https://doi.org/10.1002/jmv.25819
12. Qu R, Ling Y, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020:1-9. https://doi.org/10.1002/jmv.25767
13. Guan WJ, Zhong NS. Clinical characteristics of COVID-19 in China. Reply. N Engl J Med. 2020;382(19):1861-1862.
14. Banerjee A, Nasir JA, Budyloowski P, et al. Isolation, sequence, infectivity and replication kinetics of SARS-CoV-2. Emerg Infect Dis. 2020;26(9). https://doi.org/10.1101/2020.04.11.037382
15. Jensen IJ, Sjaastad FV, Griffith TS, et al. Sepsis-induced T cell immunoparalysis: the ins and outs of impaired T cell immunity. J Immunol. 2018;200:1543-1553.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.